Regen BioPharma Inc (RGBP)
↓ Download CSV- Sector Manufacturing
- Incorporated NV
- Fiscal year ends Sep 30
In fiscal 2025, Regen BioPharma Inc reported revenue of $236.6K, up 0.0% from the prior year. The company ran a net loss, with a net margin of -538.8%. It held $274.6K in total assets against $6.56M in total liabilities.
Key ratios (FY2025)
-143.1%
Operating margin
-538.8%
Net margin
+0.0%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $236.6K | $236.6K | $236.6K | — | — | — | — | — | — | — |
| Operating Income | -$338.5K | -$417.2K | -$687.0K | -$339.6K | -$200.8K | -$209.3K | -$756.8K | -$1.43M | -$2.51M | -$2.96M |
| Net Income | -$1.27M | -$668.3K | $1.16M | $2.44M | -$6.77M | $3.41M | -$2.62M | -$4.72M | -$5.84M | -$7.75M |
| EPS (Diluted) | $-0.05 | $-0.16 | $0.29 | $0.71 | — | — | — | — | — | — |
| Total Assets | $274.6K | $161.1K | $353.6K | $559.0K | $1.21M | $123.2K | $99.1K | $209.0K | $944.2K | $319.4K |
| Total Liabilities | $6.56M | $5.38M | $5.46M | $8.60M | $14.70M | $7.46M | $11.01M | $9.33M | $6.20M | $906.3K |
| Shareholders' Equity | -$6.28M | -$5.22M | -$5.10M | -$4.88M | -$9.76M | -$7.33M | -$7.70M | -$8.66M | -$7.80M | -$142.4K |
| Cash & Equivalents | $69.6K | $716 | $121.0K | $51.2K | $727.2K | $0 | $7.9K | $8.0K | $270.0K | $24.8K |
| Operating Cash Flow | -$383.6K | -$751.5K | -$173.9K | -$606.9K | -$1.13M | $18.6K | -$481.8K | -$1.58M | -$1.89M | -$1.67M |
| Shares Outstanding | 39.37M | 5.26M | 3.51M | 3.35M | 4.35B | 1.61B | 180.32M | 180.32M | 139.70M | 139.71M |